Initial Evaluation and Management of Infectious Mononucleosis
For a teenager or young adult presenting with fever, sore throat, cervical lymphadenopathy, and fatigue suggestive of infectious mononucleosis, begin with a complete blood count with differential and a rapid heterophile antibody (Monospot) test—this combination provides cost-effective diagnosis in most cases 1, 2.
Diagnostic Approach
Initial Laboratory Testing
The most efficient diagnostic strategy includes:
- Complete blood count with differential: Look for >40% lymphocytes AND >10% atypical lymphocytes 2
- Rapid heterophile antibody test (Monospot): Sensitivity 87%, specificity 91% 2
Key diagnostic thresholds for atypical lymphocytosis:
- ≥10% atypical lymphocytes: LR 11.4
- ≥20% atypical lymphocytes: LR 26
- ≥40% atypical lymphocytes: LR 50
- Combined finding of >50% lymphocytes AND >10% atypical lymphocytes: LR 54 3
When Heterophile Testing is Inadequate
The heterophile antibody test becomes detectable between days 6-10 after symptom onset 1. If the Monospot is negative but clinical suspicion remains high, order EBV-specific antibody testing for VCA IgM, VCA IgG, and EBNA 1.
Interpretation of EBV serology:
- VCA IgM positive (with or without VCA IgG) + EBNA negative = recent primary EBV infection
- EBNA antibodies present = infection occurred >6 weeks ago, unlikely to be causing current symptoms 1
Common pitfall: Heterophile antibodies have false-negative results in approximately 10% of patients, especially in children <10 years old 1. The presence of elevated liver enzymes increases suspicion for IM when heterophile testing is negative 2.
Clinical Examination Findings
High-Value Physical Findings
Findings that significantly increase likelihood of IM:
- Posterior cervical adenopathy: LR 3.1 (specificity 0.87) 3
- Inguinal or axillary adenopathy: LR 3.0-3.1 (specificity 0.82-0.91) 3
- Palatine petechiae: LR 5.3 (specificity 0.95) 3
- Splenomegaly: LR 1.9-6.6 (occurs in ~50% of cases) 4, 3
- Periorbital/palpebral edema (bilateral): Present in one-third of patients 4
Findings that reduce likelihood:
- Absence of any lymphadenopathy: LR 0.23-0.44 (sensitivity 0.91) 3
Less Useful Findings
Sore throat and fatigue are sensitive (0.81-0.83) but nonspecific and do not meaningfully change diagnostic probability 3.
Management
Supportive Care
Treatment is entirely supportive 2, 5:
- Adequate hydration
- Analgesics and antipyretics for symptom control
- Activity as tolerated based on patient's energy level—do not enforce strict bed rest 5
What NOT to Do
- Do not routinely use antivirals: Acyclovir inhibits EBV replication in vitro but provides no clinical benefit in immunocompetent patients 6, 5
- Do not routinely use corticosteroids: Reserve only for airway obstruction or severe pharyngeal edema 7, 5
- Do not use antihistamines 5
Activity Restrictions
Patients must avoid contact sports and strenuous exercise for 8 weeks from symptom onset or while splenomegaly persists 4, 2. Current guidelines recommend no athletic activity for 3 weeks minimum, with shared decision-making for return to activity timing 2.
Critical warning: Spontaneous splenic rupture occurs in 0.1-0.5% of cases and is potentially life-threatening 4.
Differential Diagnosis Considerations
When heterophile testing is negative, consider alternative causes of mononucleosis-like illness:
- Cytomegalovirus (especially if pharyngitis is absent)
- Toxoplasma gondii
- HIV (acute retroviral syndrome)
- Adenovirus
- Group A Streptococcus (requires throat culture/RADT) 1, 8
Special Populations
Immunocompromised patients are at higher risk of severe disease, EBV-associated lymphoproliferative disease, and significant morbidity 1, 2. In these patients, EBV viral load monitoring by NAAT may be warranted, and reduction of immunosuppression should be considered when possible 1, 7.
Prognosis
Most patients have uneventful recovery, though fatigue, myalgias, and need for sleep may persist for several months 5. IM is a risk factor for chronic fatigue syndrome 4. Long-term, EBV infection is linked to nine types of cancer (including Hodgkin lymphoma, non-Hodgkin lymphoma, nasopharyngeal carcinoma) and some autoimmune diseases 2.